OBJECTIVES: The aim of this study was to identify using implantable loop recorder (ILR) monitoring the mechanisms leading to sudden death (SD) in patients undergoing hemodialysis (HD). BACKGROUND: SD accounts for 11% to 25% of death in HD patients. METHODS: Continuous rhythm monitoring was performed using the remote monitoring capability of the ILR device in patients undergoing HD at 8 centers. Clinical, biological, and technical HD parameters were recorded and analyzed. RESULTS: Seventy-one patients (mean age 65 ± 9 years, 73% men) were included. Left ventricular ejection fraction was <50% in 16%. Twelve patients (17%) had histories of atrial fibrillation or flutter at inclusion. During a mean follow-up period of 21.3 ± 6.9 months, 16 patients died (14% patient-years), 7 (44%) of cardiovascular causes. Four SDs occurred, with progressive bradycardia followed by asystole. The incidence of patients presenting with significant conduction disorder and with ventricular arrhythmia was 14% and 9% patient-years, respectively. In multivariate survival frailty analyses, a higher risk for conduction disorder was associated with plasma potassium >5.0 mmol/l, bicarbonate <22 mmol/l, hemoglobin >11.5 g/dl, pre-HD systolic blood pressure >140 mm Hg, the longer interdialytic period, history of coronary artery disease, previous other arrhythmias, and diabetes mellitus. A higher risk for ventricular arrhythmia was associated with potassium <4.0 mmol/l, no antiarrhythmic drugs, and previous other arrhythmias. With ILR monitoring, de novo atrial fibrillation or flutter was diagnosed in 14 patients (20%). CONCLUSIONS: ILR may be considered in HD patients prone to significant conduction disorders, ventricular arrhythmia, or atrial fibrillation or flutter to allow early identification and initiation of adequate treatment. Therapeutic strategies reducing serum potassium variability could decrease the rate of SD in these patients. (Implantable Loop Recorder in Hemodialysis Patients [RYTHMODIAL]; NCT01252823).
OBJECTIVES: The aim of this study was to identify using implantable loop recorder (ILR) monitoring the mechanisms leading to sudden death (SD) in patients undergoing hemodialysis (HD). BACKGROUND: SD accounts for 11% to 25% of death in HDpatients. METHODS: Continuous rhythm monitoring was performed using the remote monitoring capability of the ILR device in patients undergoing HD at 8 centers. Clinical, biological, and technical HD parameters were recorded and analyzed. RESULTS: Seventy-one patients (mean age 65 ± 9 years, 73% men) were included. Left ventricular ejection fraction was <50% in 16%. Twelve patients (17%) had histories of atrial fibrillation or flutter at inclusion. During a mean follow-up period of 21.3 ± 6.9 months, 16 patients died (14% patient-years), 7 (44%) of cardiovascular causes. Four SDs occurred, with progressive bradycardia followed by asystole. The incidence of patients presenting with significant conduction disorder and with ventricular arrhythmia was 14% and 9% patient-years, respectively. In multivariate survival frailty analyses, a higher risk for conduction disorder was associated with plasma potassium >5.0 mmol/l, bicarbonate <22 mmol/l, hemoglobin >11.5 g/dl, pre-HD systolic blood pressure >140 mm Hg, the longer interdialytic period, history of coronary artery disease, previous other arrhythmias, and diabetes mellitus. A higher risk for ventricular arrhythmia was associated with potassium <4.0 mmol/l, no antiarrhythmic drugs, and previous other arrhythmias. With ILR monitoring, de novo atrial fibrillation or flutter was diagnosed in 14 patients (20%). CONCLUSIONS: ILR may be considered in HDpatients prone to significant conduction disorders, ventricular arrhythmia, or atrial fibrillation or flutter to allow early identification and initiation of adequate treatment. Therapeutic strategies reducing serum potassium variability could decrease the rate of SD in these patients. (Implantable Loop Recorder in Hemodialysis Patients [RYTHMODIAL]; NCT01252823).
Authors: Tara I-Hsin Chang; Sai Liu; Medha Airy; Jingbo Niu; Mintu P Turakhia; Jennifer E Flythe; Maria E Montez-Rath; Wolfgang C Winkelmayer Journal: Clin J Am Soc Nephrol Date: 2019-06-07 Impact factor: 8.237
Authors: Finnian R Mc Causland; Jim A Tumlin; Prabir Roy-Chaudhury; Bruce A Koplan; Alexandru I Costea; Vijay Kher; Don Williamson; Saurabh Pokhariyal; David M Charytan Journal: Clin J Am Soc Nephrol Date: 2020-05-07 Impact factor: 8.237
Authors: Lesley-Anne Bissell; Raluca B Dumitru; Bara Erhayiem; Giuseppina Abignano; Graham Fent; Ananth Kidambi; Helena Donica; Agata Burska; Francesco Del Galdo; John Biglands; David L Buckley; John P Greenwood; Sven Plein; Lee Graham; Maya H Buch Journal: Rheumatology (Oxford) Date: 2019-07-01 Impact factor: 7.580
Authors: Matthias C Braunisch; Christopher C Mayer; Axel Bauer; Georg Lorenz; Bernhard Haller; Konstantinos D Rizas; Stefan Hagmair; Lukas von Stülpnagel; Wolfgang Hamm; Roman Günthner; Susanne Angermann; Julia Matschkal; Stephan Kemmner; Anna-Lena Hasenau; Isabel Zöllinger; Dominik Steubl; Johannes F Mann; Thomas Lehnert; Julia Scherf; Jürgen R Braun; Philipp Moog; Claudius Küchle; Lutz Renders; Marek Malik; Georg Schmidt; Siegfried Wassertheurer; Uwe Heemann; Christoph Schmaderer Journal: Front Physiol Date: 2020-02-11 Impact factor: 4.566
Authors: Eric J Xu; LaPricia Lewis Boyer; Bernard G Jaar; Patti L Ephraim; Luis Gimenez; Alan Cheng; Jonathan Chrispin; Matthew R Weir; Dominic Raj; Eliseo Guallar; Tariq Shafi Journal: BMC Nephrol Date: 2021-05-27 Impact factor: 2.388